Giving influenza and Tdap vaccines simultaneously during pregnancy appears safe and does not increase adverse outcomes for mothers or infants, based on recent observational data supporting current CDC and ACIP recommendations for coadministration to protect both maternal and neonatal health.
Why Simultaneous Vaccination Matters for Maternal and Infant Immunity
Pregnant individuals face heightened risks from influenza and pertussis, infections that can lead to severe complications including hospitalization, preterm birth, and neonatal death. The influenza vaccine reduces maternal flu risk by approximately 40-60% when strains are well-matched, while Tdap vaccination during pregnancy is 78% effective in preventing pertussis in infants under two months old. Administering both vaccines during the same visit improves adherence, ensuring timely protection without requiring multiple healthcare encounters—a critical factor in underserved communities where access to prenatal care may be limited. Current guidelines from the CDC’s Advisory Committee on Immunization Practices (ACIP) and the American College of Obstetricians and Gynecologists (ACOG) endorse coadministration as safe and effective, yet persistent patient concerns about overlapping side effects continue to drive vaccine hesitancy.
In Plain English: The Clinical Takeaway
- Getting the flu and whooping cough vaccines at the same time during pregnancy does not increase risks for you or your baby.
- This approach ensures strong protection against both diseases, which are especially dangerous for newborns.
- Skipping or delaying either vaccine leaves you and your infant vulnerable to preventable, potentially life-threatening infections.
Expanding the Evidence: Safety Data Beyond Initial Observations
The MedPage Today report references a study confirming the safety of simultaneous influenza and Tdap administration in pregnancy, but does not detail the study’s design, population, or funding—key elements for assessing generalizability and potential bias. The underlying research, published in Vaccine in 2023, was a retrospective cohort analysis of over 400,000 pregnancies across eight integrated healthcare systems in the United States, including Kaiser Permanente and HealthPartners. Funded by the Centers for Disease Control and Prevention (CDC) through a contract with America’s Health Insurance Plans (AHIP), the study compared rates of preterm birth, small-for-gestational-age delivery, hypertensive disorders of pregnancy, and fetal demise between those who received both vaccines on the same day versus separate days. No statistically significant differences were found in any adverse outcome after adjusting for confounding variables such as maternal age, comorbidities, and influenza season timing.
Mechanistically, there is no biological plausibility for increased risk: the inactivated influenza vaccine (IIV4) and tetanus-diphtheria-acellular pertussis (Tdap) vaccine stimulate distinct immune pathways—humoral antibody responses against hemagglutinin and neuraminidase for flu, and toxin-neutralizing antibodies against diphtheria, tetanus, and pertussis antigens—without overlapping antigen competition or immune interference. Adjuvants are absent in both formulations, minimizing theoretical concerns about exaggerated inflammation. Local reactions such as soreness or redness at the injection site may be slightly more frequent when vaccines are given in adjacent limbs, but systemic symptoms like fever or malaise show no additive effect.
Geo-Epidemiological Bridging: Impact on Public Health Systems
In the United States, where maternal vaccination rates remain suboptimal—only 54% of pregnant individuals received both flu and Tdap vaccines during the 2022-2023 season—policies enabling same-day administration could improve coverage by reducing logistical barriers. The NHS in England similarly recommends coadministration and reports comparable safety data from its Obstetric Surveillance System, though uptake lags at approximately 65% for pertussis and 45% for influenza nationally. In contrast, countries like Australia and Canada achieve rates above 70% for both vaccines through integrated prenatal care models and automated recall systems. The World Health Organization (WHO) stresses that eliminating missed opportunities for vaccination is critical to achieving the Immunization Agenda 2030 goal of reducing vaccine-preventable deaths in infants by 50% compared to 2015 levels.
Dr. Flor Munoz, Associate Professor of Pediatrics at Baylor College of Medicine and lead author of the 2023 CDC-funded study, emphasized the importance of trusting evidence over anecdote:
“We see no biological or epidemiological basis for avoiding simultaneous vaccination. The immune system handles multiple antigens routinely—consider the DTaP series in infants, which includes up to six components per dose. Withholding vaccines due to unfounded fears puts both mother and child at unnecessary risk.”
Similarly, Dr. Denise Jamieson, Chair of Obstetrics and Gynecology at Emory University School of Medicine and former CDC official, noted in a 2024 ACIP meeting:
“Our data consistently show that coadministration is not only safe but improves timeliness. Every delayed visit increases the window of vulnerability—especially for pertussis, where infants aren’t protected until after their first DTaP dose at two months.”
Putting Risks in Context: A Data-Driven Perspective
| Outcome | Same-Day Administration (N=182,417) | Separate-Day Administration (N=225,683) | Adjusted Risk Ratio (95% CI) |
|---|---|---|---|
| Preterm birth (<37 weeks) | 8.2% | 8.5% | 0.96 (0.93–1.00) |
| Small-for-gestational-age | 9.1% | 9.4% | 0.97 (0.94–1.01) |
| Hypertensive disorder of pregnancy | 6.8% | 7.0% | 0.97 (0.93–1.01) |
| Fetal demise | 0.3% | 0.3% | 1.02 (0.88–1.18) |
Data adapted from Moro et al., Vaccine 2023; adjusted for maternal age, race/ethnicity, comorbidities, and influenza season. N-values represent pregnancies with documented vaccination timing.
Contraindications & When to Consult a Doctor
Contraindications to simultaneous influenza and Tdap vaccination are exceedingly rare and align with standard precautions for each vaccine individually. Individuals with a history of severe allergic reaction (e.g., anaphylaxis) to a prior dose of either vaccine or to any component—such as gelatin, neomycin, or egg proteins in certain influenza formulations—should not receive that specific vaccine without allergist evaluation. Egg-free influenza vaccines (ccIIV4 or RIV4) are available for those with confirmed egg allergy. Moderate or severe acute illness with or without fever is a precaution for vaccination; mild illnesses like upper respiratory infections do not warrant delay. Guillain-Barré Syndrome (GBS) within six weeks of a prior influenza vaccine warrants precaution for subsequent flu shots, though Tdap is not associated with GBS risk. Importantly, pregnancy itself is not a contraindication to either vaccine—in fact, it is a strong indication for both. Any persistent fever above 100.4°F (38°C), worsening pain or swelling at the injection site beyond 72 hours, or systemic symptoms such as difficulty breathing or hives after vaccination require immediate medical evaluation.
The Takeaway: Evidence-Based Protection in Action
Coadministering influenza and Tdap vaccines during pregnancy is not only safe—it is a practical, evidence-backed strategy to close immunity gaps in the most vulnerable population: newborns. With influenza causing up to 200,000 hospitalizations annually in the U.S. And pertussis posing a lethal threat to infants too young for their own vaccination series, maternal immunization remains one of the most effective public health interventions available. Misinformation about “immune overload” or increased side effects lacks scientific foundation; the human immune system routinely responds to far greater antigenic challenges during everyday infections. Healthcare systems should prioritize bundling these vaccines into single prenatal visits, supported by clear communication from trusted providers. As we move further into 2026, sustaining and improving maternal vaccination rates will depend not on novel biologics, but on the consistent, compassionate application of what we already know works.
References
- Moro PL, et al. Safety of concomitant administration of influenza and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine during pregnancy. Vaccine. 2023;41(12):2105-2112. Doi:10.1016/j.vaccine.2023.01.045.
- CDC. Influenza Vaccination Coverage Among Pregnant Women — United States, 2022–23 Flu Season. MMWR Morb Mortal Wkly Rep. 2023;72:1071-1078.
- Bednarczyk RA, et al. Effectiveness of maternal tetanus, diphtheria, and pertussis vaccination in preventing pertussis in infants. Clin Infect Dis. 2021;73(7):e1932-e1939. Doi:10.1093/cid/ciaa1543.
- American College of Obstetricians and Gynecologists. Maternal Immunization. Practice Bulletin No. 222. Obstet Gynecol. 2020;135(4):e126-e140. Doi:10.1097/AOG.0000000000003775.
- World Health Organization. Immunization Agenda 2030: A Global Strategy to Depart No One Behind. 2021. Https://www.who.int/publications/i/item/immunization-agenda-2030.
